Quantitative plasma proteome analysis reveals aberrant level of blood coagulation-related proteins in nasopharyngeal carcinoma

Journal of Proteomics

Volumn 74, Issue 5, 2011, Pages 744-757

  Peng, Pei Hua ^a   Wu, Chih Ching ^a   Liu, Shu Chen ^a   Chang, Kai Ping ^b   Chen, Chi De ^a   Chang, Ya Ting ^a   Hsu, Chia Wei ^a   Chang, Yu Sun ^a   Yu, Jau Song ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Blood coagulation; Nasopharyngeal carcinoma; Plasma kallikrein; Plasma proteome; Protein fractionation; Tumor marker

Indexed keywords

CYANINE DYE; PLASMA KALLIKREIN; PLASMA PROTEIN; PROTEOME; THROMBIN ANTITHROMBIN COMPLEX; TUMOR MARKER;

ADULT; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; BLOOD CLOTTING; CHEMICAL LABELING; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FRACTIONATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

ASIA, SOUTHEASTERN; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FEMALE; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS;

EID: 79953293308     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.02.023     Document Type: Article

References (69)

1. McDermott A.L., Dutt S.N., Watkinson J.C. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 2001, 26:82-92.
2. Cheng S.H., Jian J.J., Tsai S.Y., Yen K.L., Chu N.M., Chan K.Y., et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000, 48:1323-1330.
3. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003, 21:631-637.
4. Chang K.P., Hao S.P., Lin S.Y., Ueng S.H., Pai P.C., Tseng C.K., et al. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 2006, 116:541-546.
5. Lee A.W., Poon Y.F., Foo W., Law S.C., Cheung F.K., Chan D.K., et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992, 23:261-270.
6. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007, 6:1-9.
7. Chang Y.S., Tyan Y.S., Liu S.T., Tsai M.S., Pao C.C. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol 1990, 28:2398-2402.
8. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 1992, 3:297-307.
9. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976, 17:1-7.
10. Ho H.C., Ng M.H., Kwan H.C., Chau J.C. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976, 34:655-660.
11. Chang K.P., Hsu C.L., Chang Y.L., Tsang N.M., Chen C.K., Lee T.J., et al. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 2008, 44:784-792.
12. Chang K.P., Wu C.C., Chen H.C., Chen S.J., Peng P.H., Tsang N.M., et al. Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: potential usage of cystatin a for predicting nodal stage and poor prognosis. Proteomics 2010, 10:2644-2660.
13. Wang C.L., Wang C.I., Liao P.C., Chen C.D., Liang Y., Chuang W.Y., et al. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res 2009, 8:4428-4440.
14. Wu C.C., Hsu C.W., Chen C.D., Yu C.J., Chang K.P., Tai D.I., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 2010, 9:1100-1117.
15. Bertucci F., Birnbaum D., Goncalves A. Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics 2006, 5:1772-1786.
16. Yip T.T., Chan J.W., Cho W.C., Wang Z., Kwan T.L., Law S.C., et al. Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem 2005, 51:47-55.
17. Cho W.C., Yip T.T., Yip C., Yip V., Thulasiraman V., Ngan R.K., et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004, 10:43-52.
18. Wei Y.S., Zheng Y.H., Liang W.B., Zhang J.Z., Yang Z.H., Lv M.L., et al. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer 2008, 112:544-551.
19. Cho W.C., Yip T.T., Ngan R.K., Podust V.N., Yip C., Yiu H.H., et al. ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem 2007, 53:241-250.
20. Paweletz C.P., Wiener M.C., Sachs J.R., Meurer R., Wu M.S., Wong K.K., et al. Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose. Proteomics 2006, 6:2101-2107.
21. Cheng A.L., Huang W.G., Chen Z.C., Peng F., Zhang P.F., Li M.Y., et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008, 14:435-445.
22. Liao Q., Zhao L., Chen X., Deng Y., Ding Y. Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma. Clin Exp Metastasis 2008, 25:465-476.
23. Chen C.D., Wang C.S., Huang Y.H., Chien K.Y., Liang Y., Chen W.J., et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics 2007, 7:155-167.
24. Hwang T.L., Liang Y., Chien K.Y., Yu J.S. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006, 6:2259-2272.
25. Sun W., Xing B., Sun Y., Du X., Lu M., Hao C., et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 2007, 6:1798-1808.
26. Lilley K.S., Friedman D.B. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 2004, 1:401-409.
27. Yan J.X., Devenish A.T., Wait R., Stone T., Lewis S., Fowler S. Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics 2002, 2:1682-1698.
28. Zhou G., Li H., DeCamp D., Chen S., Shu H., Gong Y., et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124.
29. Misek D.E., Kuick R., Wang H., Galchev V., Deng B., Zhao R., et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics 2005, 5:3343-3352.
30. Wang H., Clouthier S.G., Galchev V., Misek D.E., Duffner U., Min C.K., et al. Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005, 4:618-625.
31. Kuick R., Misek D.E., Monsma D.J., Webb C.P., Wang H., Peterson K.J., et al. Discovery of cancer biomarkers through the use of mouse models. Cancer Lett 2007, 249:40-48.
32. Wu C.C., Peng P.H., Chang Y.T., Huang Y.S., Chang K.P., Hao S.P., et al. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation. Proteomics 2008, 8:3605-3620.
33. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
34. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658.
35. Chang K.P., Hao S.P., Chang J.H., Wu C.C., Tsang N.M., Lee Y.S., et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. Clin Cancer Res 2008, 14:6979-6987.
36. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
37. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
38. Echan L.A., Tang H.Y., Ali-Khan N., Lee K., Speicher D.W. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005, 5:3292-3303.
39. Tang H.Y., Ali-Khan N., Echan L.A., Levenkova N., Rux J.J., Speicher D.W. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 2005, 5:3329-3342.
40. Qian W.J., Kaleta D.T., Petritis B.O., Jiang H., Liu T., Zhang X., et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 2008, 7:1963-1973.
41. Fardin P., Moretti S., Biasotti B., Ricciardi A., Bonassi S., Varesio L. Normalization of low-density microarray using external spike-in controls: analysis of macrophage cell lines expression profile. BMC Genomics 2007, 8:17.
42. Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002, 32:496-501.
43. MacCoss M.J., Wu C.C., Yates J.R. Probability-based validation of protein identifications using a modified SEQUEST algorithm. Anal Chem 2002, 74:5593-5599.
44. Chen P. Serum acute phase proteins in nasopharyngeal carcinoma and laryngeal cancers. Zhonghua Er Bi Yan Hou Ke Za Zhi 1989;24:174-6, 90.
45. Wolf G.T., Wolfe R.A. Circulating immune complexes in patients with nasopharyngeal carcinoma. Laryngoscope 1990, 100:302-308.
46. Heo S.H., Lee S.J., Ryoo H.M., Park J.Y., Cho J.Y. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007, 7:4292-4302.
47. Okano T., Kondo T., Kakisaka T., Fujii K., Yamada M., Kato H., et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6:3938-3948.
48. Habermann J.K., Roblick U.J., Luke B.T., Prieto D.A., Finlay W.J., Podust V.N., et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 2006, 131:1020-1029. quiz 284.
49. Lee I.N., Chen C.H., Sheu J.C., Lee H.S., Huang G.T., Chen D.S., et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006, 6:2865-2873.
50. Ali O.S., Abo-Shadi M.A., Hammad L.N. The biological significance of serum complements C3 and C4 in HCV-related chronic liver diseases and hepatocellular carcinoma. Egypt J Immunol 2005, 12:91-99.
51. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999, 36:929-939.
52. Verhaegen H., De Cock W., De Cree J., Verbruggen F. Increase of serum complement levels in cancer patients with progressing tumors. Cancer 1976, 38:1608-1613.
53. Huang G.W., Nong H.T., Nakamura M., Kosugi T. Enhancement of platelet aggregation in patients with nasopharyngeal carcinoma. Auris Nasus Larynx 1994, 21:173-177.
54. Kosugi T., Takagi I., Ariga Y., Okada S., Morimitsu T., Mihara H. Fibrinolysis-coagulation system in patients with cancer of the head and neck. Preliminary report. Arch Otorhinolaryngol 1982, 236:211-215.
55. Camerer E., Qazi A.A., Duong D.N., Cornelissen I., Advincula R., Coughlin S.R. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004, 104:397-401.
56. Janowska-Wieczorek A., Wysoczynski M., Kijowski J., Marquez-Curtis L., Machalinski B., Ratajczak J., et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005, 113:752-760.
57. Rickles F.R., Patierno S., Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 2003, 124:58S-68S.
58. Palumbo J.S., Kombrinck K.W., Drew A.F., Grimes T.S., Kiser J.H., Degen J.L., et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309.
59. Dardik R., Kaufmann Y., Savion N., Rosenberg N., Shenkman B., Varon D. Platelets mediate tumor cell adhesion to the subendothelium under flow conditions: involvement of platelet GPIIb-IIIa and tumor cell alpha(v) integrins. Int J Cancer 1997, 70:201-207.
60. Felding-Habermann B., Ruggeri Z.M., Cheresh D.A. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 1992, 267:5070-5077.
61. Wang J.S., Chang C.Y., Chow S.E., Chen Y.W., Yang C.M. Exercise modulates platelet-nasopharyngeal carcinoma cell aggregation and subsequent tissue factor and matrix metalloproteinase activities. J Appl Physiol 2007, 103:763-770.
62. Roselli M., Mineo T.C., Basili S., Mariotti S., Martini F., Bellotti A., et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 2003, 89:177-184.
63. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005, 102:7677-7682.
64. Chung D.W., Fujikawa K., McMullen B.A., Davie E.W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986, 25:2410-2417.
65. Lilla J.N., Joshi R.V., Craik C.S., Werb Z. Active plasma kallikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution. J Biol Chem 2009, 284:13792-13803.
66. Almeida P.C., Chagas J.R., Cezari M.H., Juliano M.A., Juliano L. Hydrolysis by plasma kallikrein of fluorogenic peptides derived from prorenin processing site. Biochim Biophys Acta 2000, 1479:83-90.
67. Peek M., Moran P., Mendoza N., Wickramasinghe D., Kirchhofer D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J Biol Chem 2002, 277:47804-47809.
68. Colman R.W. Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des 2006, 12:2599-2607.
69. Chee J., Naran A., Misso N.L., Thompson P.J., Bhoola K.D. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 2008, 389:1225-1233.